Bernard Gilly, Gensight CEO (Eric Piermont/AFP via Getty Images)
December 15, 2020 02:13 PM ESTUpdated February 11, 03:20 PM
Discovery
In Focus

They thought their gene ther­a­py failed. In­stead, it spawned a med­ical mys­tery

Jason Mast

Editor

José-Alain Sa­hel was on a rare va­ca­tion in Por­tu­gal in the spring of 2018 when his phone rang with grim news: The gene ther­a­py he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times